AHT Stock Chart & Stats
€57.00
-€2.00(-3.39%)
At close: 4:00 PM EDT
€57.00
-€2.00(-3.39%)
Day’s Range― - ―
52-Week Range€40.40 - €65.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.96B
Enterprise Value€4.02K
Total Cash (Recent Filing)€440.00M
Total Debt (Recent Filing)€1.48B
Price to Earnings (P/E)65.5
Beta0.64
Next Earnings
Nov 10, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding45,793,370
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.16
Price to Sales (P/S)1.21
P/FCF Ratio-550.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€68.72Price Target Upside20.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)3.07
Revenue Forecast (FY)€1.62B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow provides durable financial flexibility: it funds capex, deleveraging, dividends or M&A without relying solely on capital markets. High quarterly conversion (>90%) and management's >50% adj. EBITDA FCF target underpin repeatable cash conversion capacity.
Life Sciences OutperformanceA high-margin, regulated Life Sciences franchise showing consecutive volume growth supports durable revenue mix improvement. Strong adoption of injectables and high‑purity excipients makes revenues stickier via qualification cycles, improving long-term margin resilience and reducing cyclicality versus commodity exposures.
Improved Governance And Capital ToolsBoard refreshment and a dedicated capital allocation committee increase oversight and discipline on long‑term strategy and deployment of cash. Combined with activist cooperation and explicit committee oversight, this structurally raises likelihood of value‑focused decisions and clearer capital priorities over coming years.
Bears Say
Higher Leverage Vs Prior YearsMaterial increase in leverage reduces financial optionality and raises interest and refinancing sensitivity. Even if solvency is presently acceptable, higher indebtedness constrains capital allocation choices, limits ability to absorb shocks, and makes sustained investment or M&A more conditional on steady cash generation.
Volatile Profitability And Modest MarginsLarge swings from deep loss to modest TTM profitability indicate earnings are not yet structurally stable. Modest net margins and episodic negative results complicate forecasting, reduce retained earnings growth, and heighten execution risk when funding reinvestment or servicing debt through downcycles.
Ongoing Manufacturing / Optimization DelaysPersistent plant ramp issues and delayed network optimization materially compress margins and delay realization of structural cost savings. Slower operational improvement prolongs fixed‑cost underabsorption, keeping adjusted EBITDA and margin recovery contingent on execution risks across multiple quarters.
Ashland News
AHT FAQ
What was Ashland’s price range in the past 12 months?
Ashland lowest stock price was €40.40 and its highest was €65.50 in the past 12 months.
What is Ashland’s market cap?
Ashland’s market cap is €2.96B.
When is Ashland’s upcoming earnings report date?
Ashland’s upcoming earnings report date is Nov 10, 2026 which is in 89 days.
How were Ashland’s earnings last quarter?
Ashland released its earnings results on Jul 28, 2026. The company reported €0.883 earnings per share for the quarter, beating the consensus estimate of €0.853 by €0.03.
Is Ashland overvalued?
According to Wall Street analysts Ashland’s price is currently Undervalued.
Does Ashland pay dividends?
Ashland does not currently pay dividends.
What is Ashland’s EPS estimate?
Ashland’s EPS estimate is 1.12.
How many shares outstanding does Ashland have?
Ashland has 45,793,370 shares outstanding.
What happened to Ashland’s price movement after its last earnings report?
Ashland reported an EPS of €0.883 in its last earnings report, beating expectations of €0.853. Following the earnings report the stock price went up 2.632%.
Which hedge fund is a major shareholder of Ashland?
Currently, no hedge funds are holding shares in DE:AHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ashland Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€68.72 (20.56% Upside)
€68.72 (20.56% Upside)
Blogger Sentiment
Neutral
DE:AHT Sentiment 57%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.37%
12-Months-Change
Fundamentals
Return on Equity
2.21%
Trailing 12-Months
Asset Growth
-0.93%
Trailing 12-Months
Company Description
Ashland
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical formulations, encompassing controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and binding agents for tablets. It also offers nutritional compounds like thickeners, stabilizers, emulsifiers, and various additives, alongside nutraceutical items designed for weight management, joint comfort, gastrointestinal health, sports nutrition, and general well-being. Additionally, this division provides custom formulation services, toll processing, and particle engineering expertise. The Personal Care & Household division manufactures a diverse array of naturally derived, biodegradable, and high-performance ingredients for personal care products. Its offerings extend to solutions for oral hygiene, such as toothpastes, mouthwashes, denture cleansers, and general dental care. For household applications, it supplies nature-sourced rheology modifiers, biodegradable wetting agents for surfaces, advanced encapsulants, and specialized polymers. The Specialty Additives segment's portfolio includes rheology modifiers, agents for foam control, surfactants, wetting agents, pH neutralizers, and advanced ceramic materials, which find application in catalytic converters, environmental filters, components for ceramic capacitors, plasma display panels, and solar cells. Furthermore, it supplies ingredients for textile printing, thermoplastic metals, and alloys utilized in welding processes. The Intermediates and Solvents division is responsible for producing 1,4 butanediol and its associated derivatives, notably n-methylpyrrolidone. Ashland's diverse product portfolio serves clientele across numerous consumer and industrial sectors, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceuticals. The company, previously known as Ashland Global Holdings Inc., was established in Wilmington, Delaware, in 1924.
AHT Company Deck
AHT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of clear commercial and cash-generation strengths—broad-based revenue growth (7% YoY), strong Life Sciences and Personal Care performance, inventory reduction, improved liquidity and the successful execution of Globalize and Innovate initiatives—while also acknowledging material margin pressure from earlier production disruptions, lower adjusted EBITDA versus last year, EPS headwinds from a higher tax rate, and slower-than-expected operational improvements in certain plants (notably Hopewell/HEC). Management expects pricing realization and manufacturing improvements to support a step-up in profitability in Q4 and reaffirmed revenue and EBITDA guidance, but timing of full margin recovery remains uncertain.View all DE:AHT earnings summariesAHT Stock 12 Month Forecast
Average Price Target
€68.72
▲(20.56% Upside)